Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum 9 Meters Biopharma Inc NMTRQ

9 Meters Biopharma, Inc. has ceased operations. The Company has filed a voluntary petition for relief under provisions of Chapter 7 of Title 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the Eastern District of North Carolina.

GREY:NMTRQ - Post Discussion

9 Meters Biopharma Inc > Trending Upwards
View:
Post by Bagofhammers on Oct 04, 2020 11:54am

Trending Upwards

This has been pegged at @ $10 s/p. The trend is indicating as such over the long term. Currently 150 patents worldwide.

https://9meters.com
Comment by kalareta on Oct 04, 2020 1:44pm
I hope so. Couple years ago was 35 dol. per share.
Comment by Shortandcollect on Oct 04, 2020 9:06pm
Going down to 50 cents Bago. Shorting again.
Comment by kalareta on Oct 05, 2020 8:26am
Good then we will load more.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities